A new horizon for Sjögren's disease: the FDA breakthrough designation of ianalumab.

Ann Med Surg (Lond) · 2026 · PMC13132268 · PMID 42078617

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In NEPTUNUS-2, although patient-reported outcomes improved numerically, the differences did not reach statistical significance, suggesting potential heterogeneity in treatment response[ 5 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.